Condition: Prognostic Cancer Model · Sponsor: Interni hematologicka klinika FNKV
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.
This description comes directly from the study's public registry record.
Heidi Mocikova, M.D., Ph.D. · +420267163554 · heidi.mocikova@fnkv.cz
Ondrej Havranek, assoc. prof. · +420325873029 · ondrej.havranek@lf1.cuni.cz
Always discuss trial participation with your own doctor first.
| University Hospital Hradec Kralove | Hradec Králové, Czechia | Recruiting |
| University Hospital Olomouc | Olomouc, Czechia | Recruiting |
| University Hospital Kralovske Vinohrady | Prague, Czechia | Recruiting |
| Charles University | Prague, Czechia | Active Not Recruiting |
| General University Hospital | Prague, Czechia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06263530